Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen | Zendy

Ayman Sakr | Zendy; Jasmine Hanifi | Zendy; Ming Lin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Successful Treatment of Mixed Hepatitis C Genotypes in a Cirrhotic Patient With an All-Oral, Interferon-Free Regimen

Author(s) -

Ayman Sakr,

Jasmine Hanifi,

Ming Lin

Publication year - 2017

Publication title -

acg case reports journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.112

H-Index - 4

ISSN - 2326-3253

DOI - 10.14309/crj.2017.16

Subject(s) - medicine , sofosbuvir , ledipasvir , ribavirin , daclatasvir , hepatitis c virus , regimen , genotype , hepatitis c , gastroenterology , virology , immunology , virus , biochemistry , chemistry , gene

Mixed hepatitis C virus (HCV) genotype infection is emerging with improved methods of detection. It is commonly seen in hemodialysis patients and intravenous drug users due to repeated HCV exposure and absence of protective immunity, and can contribute to treatment failure. Direct-acting antiviral regimens have been extensively studied in patients with different individual HCV genotypes; however, there are no reported data on their use in patients with mixed HCV genotype. We present a case of mixed HCV genotype 1a and 2 infection in a decompensated cirrhotic patient treated successfully with sofosbuvir, ledipasvir, and ribavirin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research